Sonoma Pharmaceuticals, Inc. (SNOA) News
Filter SNOA News Items
SNOA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SNOA News From Around the Web
Below are the latest news stories about SONOMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SNOA as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the hottest trading news for Tuesday morning! |
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial ResultsGross profit percentage of 36% for the quarter, up 1% from first fiscal quarter 2024Total operating expenses decreased for the quarter and six months ended September 30, 2023 compared to same period prior yearEuropean revenues increased 3% for the ... |
Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall ConferenceBOULDER, CO / ACCESSWIRE / November 3, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... |
Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common StockBOULDER, CO / ACCESSWIRE / October 26, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ... |
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceJUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand Hotel in Jupiter, FL. Dawson James’ flagship Small Cap Growth Conference brings together senior leadership from over 30 of the most innovative companies at the forefront of healthcare, technology and consu |
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn AdvancedSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced that Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel has received the National Eczema |
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended June 30, 2023. |
Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory BoardSonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced the appointment of Dr. Hye Jin Chung MD, MMSc, Assistant Professor of Dermatology at Harvard |
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial ResultsSonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2023 and the fourth quarter ended March 31, 2023. |
Sonoma Pharmaceuticals Shares Soar 44% After Introducing New ProductSonoma Pharmaceuticals shares jumped 44% on Friday after the company unveiled a product that could replace IV bags for some surgeries. |